多发性硬化症的疾病修正治疗和 SARS-CoV-2 疫苗接种：专家共识。
Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus.
机构信息
Department of Systems Medicine, Tor Vergata University, Rome, Italy.
Unit of Neurology, IRCCS Neuromed, Pozzilli (IS), Italy.
出版信息
J Neurol. 2021 Nov;268(11):3961-3968. doi: 10.1007/s00415-021-10545-2. Epub 2021 Apr 12.
Abstract
Coronavirus disease (COVID-19) appeared in December 2019 in the Chinese city of Wuhan and has quickly become a global pandemic. The disease is caused by the severe acute respiratory syndrome coronavirus type-2 (SARS-CoV-2), an RNA beta coronavirus phylogenetically similar to SARS coronavirus. To date, more than 132 million cases of COVID19 have been recorded in the world, of which over 2.8 million were fatal ( https://coronavirus.jhu.edu/map.html ). A huge vaccination campaign has started around the world since the end of 2020. The availability of vaccines has raised some concerns among neurologists regarding the safety and efficacy of vaccination in patients with multiple sclerosis (MS) taking immunomodulatory or immunosuppressive therapies.
摘要
冠状病毒病（COVID-19）于 2019 年 12 月在中国武汉市出现，并迅速成为全球性大流行。该疾病由严重急性呼吸系统综合征冠状病毒 2 型（SARS-CoV-2）引起，这是一种 RNA 乙型冠状病毒，在系统发育上与严重急性呼吸系统综合征冠状病毒相似。迄今为止，全世界已记录超过 1.32 亿例 COVID-19 病例，其中超过 280 万人死亡（https://coronavirus.jhu.edu/map.html）。自 2020 年底以来，全球已开始大规模接种疫苗。疫苗的出现引起了一些神经科医生对接受免疫调节或免疫抑制治疗的多发性硬化症（MS）患者疫苗接种安全性和有效性的关注。
相似文献
1
Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus.
J Neurol. 2021 Nov;268(11):3961-3968. doi: 10.1007/s00415-021-10545-2. Epub 2021 Apr 12.
2
Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination.
CNS Drugs. 2020 Sep;34(9):879-896. doi: 10.1007/s40263-020-00756-y.
3
[Vaccination against SARS-CoV-2 in patients with multiple sclerosis].
Rev Neurol. 2021 Apr 1;72(7):250-260. doi: 10.33588/rn.7207.2021097.
4
Multiple sclerosis in the era of COVID-19: disease course, DMTs and SARS-CoV2 vaccinations.
Curr Opin Neurol. 2022 Jun 1;35(3):319-327. doi: 10.1097/WCO.0000000000001066.
5
Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in.
Front Immunol. 2022 Oct 17;13:1045101. doi: 10.3389/fimmu.2022.1045101. eCollection 2022.
6
COVID-19 vaccination in patients with multiple sclerosis receiving disease-modifying therapies: pragmatic issues.
Drugs Today (Barc). 2022 Dec;58(12):605-620. doi: 10.1358/dot.2022.58.12.3455368.
7
Vaccination Setting of Patients with Autoimmune Diseases in Times of Severe Acute Respiratory Syndrome Coronavirus Type 2 Pandemic Using the Example of Multiple Sclerosis Patients: A Longitudinal Multicenter Study.
Eur Neurol. 2022;85(2):104-111. doi: 10.1159/000519582. Epub 2021 Nov 5.
8
Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis.
Front Immunol. 2021 Jun 21;12:701752. doi: 10.3389/fimmu.2021.701752. eCollection 2021.
9
Summary of Safety and Efficacy of COVID Vaccination in Patients with Multiple Sclerosis.
Eur Neurol. 2023;86(4):263-276. doi: 10.1159/000529982. Epub 2023 Mar 4.
10
A retrospective evaluation of seroconversion after COVID-19 during the early Omicron wave in fully vaccinated multiple sclerosis patients receiving anti-CD20 therapies.
Mult Scler Relat Disord. 2023 Mar;71:104574. doi: 10.1016/j.msard.2023.104574. Epub 2023 Feb 15.
引用本文的文献
1
COVID-19 Vaccine Boosters in People With Multiple Sclerosis: Improved SARS-CoV-2 Cross-Variant Antibody Response and Prediction of Protection.
Neurol Neuroimmunol Neuroinflamm. 2025 Sep;12(5):e200443. doi: 10.1212/NXI.0000000000200443. Epub 2025 Jul 22.
2
Impact of High-Efficacy Therapies for Multiple Sclerosis on B Cells.
Cells. 2025 Apr 17;14(8):606. doi: 10.3390/cells14080606.
3
COVID-19 vaccination in patients with multiple sclerosis: what you need to know - a review.
Health Sci Rep. 2024 Oct 6;7(10):e70119. doi: 10.1002/hsr2.70119. eCollection 2024 Oct.
4
Immunosenescence and vaccine efficacy revealed by immunometabolic analysis of SARS-CoV-2-specific cells in multiple sclerosis patients.
Nat Commun. 2024 Mar 29;15(1):2752. doi: 10.1038/s41467-024-47013-0.
5
Drugs Targeting CD20 in Multiple Sclerosis: Pharmacology, Efficacy, Safety, and Tolerability.
Drugs. 2024 Mar;84(3):285-304. doi: 10.1007/s40265-024-02011-w. Epub 2024 Mar 14.
6
Humoral and T-cell response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients: Correlations with DMTs and clinical variables.
Neurotherapeutics. 2024 Mar;21(2):e00307. doi: 10.1016/j.neurot.2023.e00307. Epub 2023 Dec 19.
7
ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs.
Mult Scler. 2023 Jul;29(8):904-925. doi: 10.1177/13524585231168043. Epub 2023 Jun 9.
8
T cell responses to SARS-CoV-2 vaccination differ by disease-modifying therapy for multiple sclerosis.
JCI Insight. 2023 Jun 22;8(12):e165111. doi: 10.1172/jci.insight.165111.
9
Humoral efficacy of the third SARS-CoV-2 vaccine dose in Multiple Sclerosis subjects undergoing different disease-modifying therapies.
Mult Scler Relat Disord. 2022 Dec;68:104371. doi: 10.1016/j.msard.2022.104371. Epub 2022 Oct 23.
10
Assessing the immune response to SARS-CoV-2 mRNA vaccines in siponimod-treated patients: a nonrandomized controlled clinical trial (AMA-VACC).
Ther Adv Neurol Disord. 2022 Nov 8;15:17562864221135305. doi: 10.1177/17562864221135305. eCollection 2022.
本文引用的文献
1
Varicella zoster virus and influenza vaccine antibody titres in patients from MAGNIFY-MS who were treated with cladribine tablets for highly active relapsing multiple sclerosis.
Mult Scler. 2022 Nov;28(13):2151-2153. doi: 10.1177/13524585221099413. Epub 2022 Jun 7.
2
Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients.
Natl Sci Rev. 2020 Jun;7(6):998-1002. doi: 10.1093/nsr/nwaa041. Epub 2020 Mar 13.
3
COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study.
Lancet Rheumatol. 2021 Jun;3(6):e419-e426. doi: 10.1016/S2665-9913(21)00059-X. Epub 2021 Mar 25.
4
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.
CNS Drugs. 2021 Mar;35(3):317-330. doi: 10.1007/s40263-021-00804-1. Epub 2021 Mar 20.
5
Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis.
JAMA Neurol. 2021 Jun 1;78(6):699-708. doi: 10.1001/jamaneurol.2021.0688.
6
COVID-19 in multiple sclerosis patients treated with dimethyl fumarate.
J Neurol. 2021 Sep;268(9):3132-3134. doi: 10.1007/s00415-021-10446-4. Epub 2021 Feb 20.
7
COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review.
Mult Scler Relat Disord. 2021 May;50:102800. doi: 10.1016/j.msard.2021.102800. Epub 2021 Jan 29.
8
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis.
Ann Neurol. 2021 Apr;89(4):780-789. doi: 10.1002/ana.26028. Epub 2021 Feb 9.
9
COVID-19 in teriflunomide-treated patients with multiple sclerosis: A case report and literature review.
Mult Scler Relat Disord. 2021 Feb;48:102734. doi: 10.1016/j.msard.2020.102734. Epub 2021 Jan 2.
10
Neurological infection with SARS-CoV-2 - the story so far.
Nat Rev Neurol. 2021 Feb;17(2):65-66. doi: 10.1038/s41582-020-00453-w.
Zotero 插件